Kamada (NASDAQ:KMDA) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDA) in a research report sent to investors on Thursday morning. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, May 9th.

Kamada Trading Down 1.8 %

Kamada stock opened at $4.96 on Thursday. The stock has a market cap of $285.10 million, a P/E ratio of 21.57 and a beta of 1.06. The stock has a 50 day moving average of $5.27 and a 200-day moving average of $5.63. Kamada has a 52 week low of $4.08 and a 52 week high of $6.53.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). Kamada had a net margin of 8.33% and a return on equity of 5.50%. The business had revenue of $37.74 million for the quarter, compared to analyst estimates of $38.01 million. As a group, equities analysts predict that Kamada will post 0.26 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. EWA LLC bought a new stake in Kamada during the 4th quarter worth approximately $68,000. Calton & Associates Inc. purchased a new stake in shares of Kamada during the fourth quarter worth $111,000. Y.D. More Investments Ltd lifted its position in shares of Kamada by 107.1% during the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after acquiring an additional 15,000 shares in the last quarter. Aristides Capital LLC lifted its position in shares of Kamada by 41.6% during the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 16,635 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares in the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.